Table 2 Recommended reforms for the current medical cannabis stream

• Encourage documentation and reporting by healthcare providers (HCPs), such as when new observations are made regarding the use of medical cannabis

• Mandate adverse event reporting by HCPs through the Canada Vigilance Program

• Increase the involvement of pharmacists in the dispensation of cannabis, screening for drug interactions, and on provision of counseling for medical cannabis

• Encourage colleges of pharmacists to strongly encourage cannabis education for pharmacists

• Mandate reporting of serious adverse effects associated with medical cannabis by pharmacists and other healthcare providers

• Create a simplified authorization process to help clinicians and create a medical document emulating a standard medical “prescription” which specifies a total quantity of each cannabinoid and clear dosing instructions

• Remove the tax on medical cannabis

• Reform the Cannabis Act to permit the use of Good Production Practices (GPP) cannabis clinical research

• Review the quality control regulations of products under the Access to Cannabis for Medical Purposes Regulations (ACMPR) or the Cannabis Act

• Incorporate the consumer health products framework, which will have impact on medical access to cannabidiol (CBD) products and allow the ACMPR to focus on access to delta-9 tetrahydrocannabinol (THC)

• Expand all forms of research, including that on harm reduction and cost-effectiveness of cannabis

• Take into consideration the perspectives of diverse patient representatives prior to implementing changes to the Cannabis Act